Providing knowledge and clarity to make the right strategic decisions
Deallus is a Celtic word meaning ‘intelligent’, ‘understanding’ and ‘wise’
These qualities underpin the strategic intelligence we provide, enabling you to make the right decisions and gain distinct competitive advantages in increasingly complex and dynamic marketplaces.
Since our inception as a competitive intelligence provider we have grown and developed our offerings to include strategic guidance and partnership.
Strategic Intelligence. Competitive Advantage.
The term strategic intelligence, common in military circles, refers to the collection, processing, analysis, and dissemination of intelligence to equip leaders to be effective strategists.
We bring strategic intelligence to the life sciences sector by providing clients with the knowledge and clarity they need to make the right strategic decisions in order to gain distinct competitive advantages.
Our global presence
With seven offices across four continents, and over 25 languages spoken, we are able to offer global support as well as work as one global team, collaborating and sharing our expertise across geographies.
Featured Dealli
Pete Hempshall
Pete Hempshall, MEng is Deallus Chief Executive Officer, based in London.
Julie Munch Khan
Julie Munch Khan is Deallus Chief Commercial Officer, based in London.
Stephen Cherry
Stephen Cherry is Chief Financial Officer for Deallus, based in London.
Peter Barschdorff
Peter Barschdorff is Deallus Vice President (U.S.), based in New York.
“Deallus was appointed to help us create a market access strategy when we were planning to enter a number of key emerging markets. The insights and analysis they provided equipped us with an in-depth understanding of the competitive landscape, key stakeholders, pricing, and patient flow. On top of this they conceived an invaluable strategic roadmap for entry into each market. Deallus’ contribution was certainly outstanding as they helped us successfully drive access and uptake globally.”
Director of Global Market Access, Top 20 pharma company